FDA's ability to regulate off-label promotion by pharmaceutical companies is dwindling, primarily because of First Amendment legal challenges by the industry. The FDA may not win this First Amendment battle and has hinted in a public hearing notice that it may have to allow pharma companies to engage in off-label communications directly to "patients and consumer adudiences" and not just to physicians (read about that here).

This survey asks your input to specific questions FDA has regarding off-label communications to consumers. This issue will be discussed at a November, 9 - 10, 2016, public hearing at FDA and the results of this survey may be submitted to the comment docket and/or presented at that hearing and summarized in Pharma Marketing News.

After you complete the survey, you will be able to see a summary of up-to-date results.  No comments or other identifying information is included in the summary.

Your comments are confidential (anonymous) unless you specifically provide your contact information at the end of the survey and allow us to attribute comments to you personally.

Click on the "Next" button below to continue.


John Mack
Editor, Pharma Marketing News